Press Releases

2013 Press Releases 

 

April 15, 2013

Merrimack Pharmaceuticals Completes Enrollment of One Cohort in Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer

April 10, 2013

Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2 targeted Treatment In Gastric Cancer Model

April 8, 2013

Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model

April 5, 2013

Merrimack Pharmaceuticals Announces Webcast of Inaugural Research & Development Day

April 4, 2013

Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor

April 2, 2013

Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies

March 18, 2013

Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Paclitaxel in Patients iwth Platinum-Resistant or Refractory Advanced Ovarian Cancers

March 14, 2013

Merrimack Reports Fourth Quarter and Full Year 2012 Financial Results

February 27, 2013

Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2012 Investor Conference Call 

February 25, 2013

Merrimack to Present at Cowen and Company 33rd Annual Health Care Conference

February 7, 2013

Merrimack to Participate in Pancreatic Cancer Panel at the 2013 BIO CEO & Investor Conference

January 23, 2013

Merrimack Pharmaceuticals to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers

 

 

 

 

Related Content

Archived Press Releases